SANTA CLARA, Calif. & GREIFSWALD, Germany– Greifswald-based medical technology pioneer Neoplas Med GmbH is intensifying its strategic collaboration with Niterra Ventures Company, via an $18M capital increase to expand the market further for innovative wound care technology products. With a total investment of $25M, Niterra Ventures Company previously invested in Neoplas Med in 2022 and 2023.
Neoplas Med, which emerged from the Leibniz Institute for Plasma Science and Technology e.V. (INP), has created the argon cold plasma jet, kINPen® MED, an innovative ‘plasma pen’ that directs a precise plasma jet onto wounds and significantly accelerates wound healing. Clinical studies show that treatment time can be reduced by 50% compared to conventional methods – without side effects or developing resistance. Neoplas Med is almost the only company that uses the inert gas argon for this almost painless and rapid therapy, treating both infected and chronic wounds. With its ‘plasma pen,’ Neoplas Med GmbH is the only manufacturer of cold plasma products in Europe that is European Medical Device Regulation (MDR) certified.
“The additional investment by Niterra Ventures Company opens up completely new opportunities for us to tap into further markets, expand our technology platform and develop new products,” said Ulrike Sailer, CEO of Neoplas Med. “We are not only taking a big step forward, but also securing and creating new jobs in the high-tech sector.”
In Germany, 75% of university clinics and numerous medical practices and hospitals utilize Neoplas Med’s patented Argon Jet cold plasma therapy, which has been used in more than 500,000 treatments worldwide, including in leading clinics in the Middle East. This funding will be used to further develop its technology platform and scale operations internationally, focusing primarily on the US, Europe and Middle East.
“Niterra Ventures Company is establishing new business opportunities in the medical, cleantech, energy and IoT sectors to improve quality of life using cutting-edge technologies,” said Dirk Schapeler, president of Niterra Ventures Company. “We have been working closely with Neoplas Med over the last few years and are excited to see the impact of the Kinpen argon cold plasma on patients. Therefore, our follow on investment was a logical step.”
As a part of its effort in medical, Niterra Ventures Company is investing in technology detecting and assessing cardiology, oncology, neurology and hypertension conditions.
